{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04634825",
      "orgStudyIdInfo": {
        "id": "CP-MGA271-06"
      },
      "organization": {
        "fullName": "MacroGenics",
        "class": "INDUSTRY"
      },
      "briefTitle": "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer",
      "officialTitle": "A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-12",
      "overallStatus": "TERMINATED",
      "whyStopped": "Based on internal review of safety data",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-03-17",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2022-07-29",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-07-29",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-11-12",
      "studyFirstSubmitQcDate": "2020-11-12",
      "studyFirstPostDateStruct": {
        "date": "2020-11-18",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2023-05-30",
      "resultsFirstSubmitQcDate": "2023-12-18",
      "resultsFirstPostDateStruct": {
        "date": "2023-12-20",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-12-18",
      "lastUpdatePostDateStruct": {
        "date": "2023-12-20",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "MacroGenics",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    "conditionsModule": {
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Neoplasms",
        "Head and Neck Squamous Cell Carcinoma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Enrollment into each cohort will occur independently in a non-randomized fashion, based on PD-L1 expression results. Patients may not crossover between cohorts.",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 62,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Retifanlimab Cohort",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles",
          "interventionNames": [
            "Biological: Enoblituzumab",
            "Biological: Retifanlimab"
          ]
        },
        {
          "label": "Tebotelimab Cohort",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles",
          "interventionNames": [
            "Biological: Enoblituzumab",
            "Biological: Tebotelimab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Enoblituzumab",
          "description": "Anti-B7-H3 antibody",
          "armGroupLabels": [
            "Retifanlimab Cohort",
            "Tebotelimab Cohort"
          ],
          "otherNames": [
            "MGA271"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Retifanlimab",
          "description": "Anti-PD-1 antibody",
          "armGroupLabels": [
            "Retifanlimab Cohort"
          ],
          "otherNames": [
            "INCMGA00012",
            "MGA012",
            "Zynyz"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Tebotelimab",
          "description": "PD-1 X LAG-3 bispecific DART molecule",
          "armGroupLabels": [
            "Tebotelimab Cohort"
          ],
          "otherNames": [
            "MGD013"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Overall Response Rate (ORR) of Enoblituzumab Plus Retifanlimab",
          "description": "Investigator-assessed ORR. defined as the percentage of patients in the response evaluable population who achieve the best overall response of complete response (CR) or partial response (PR),per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria..\n\nCR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months."
        },
        {
          "measure": "Number of Patients With Adverse Events (AEs) Receiving Enoblituzumab Plus Tebotelimab",
          "timeFrame": "Throughout the study, up to 16.5 months."
        },
        {
          "measure": "ORR of Enoblituzumab Plus Tebotelimab",
          "description": "Investigator-assessed ORR. ORR, defined as the percentage of patients in the response evaluable population who achieve the a best overall response of complete response (CR) or partial response (PR), per RECIST, version 1.1 criteria.\n\nCR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Progression-free Survival (PFS)",
          "description": "Time from the first dose date to the date of first documented progression or death from any cause, whichever occurs first, evaluated by cohort",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months"
        },
        {
          "measure": "Disease-control Rate (DCR)",
          "description": "Percentage of response-evaluable patients with CR, PR, or stable disease (SD) for at least 3 months, evaluated by cohort",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months"
        },
        {
          "measure": "Duration of Response",
          "description": "Time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first, evaluated by cohort",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months"
        },
        {
          "measure": "Overall Survival",
          "description": "Time from the first dose date to the date of death from any cause, evaluated by cohort",
          "timeFrame": "up to 16.5 months"
        },
        {
          "measure": "Best Overall Response (BOR)",
          "description": "The participants best response to treatment during their study participation. Responses are categorized as CR, PR, stable disease (SD), progressive disease (PD), or not evaluated (NE), per RECIST 1.1 criteria CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions, and non-PD in non-target lesions PD is defined as at least a 20% increase from nadir in the sum of diameters of target lesions or unequivocal progression in non-target lesions SD is defined as non-PD in target and non-target lesions",
          "timeFrame": "Tumor assessment is conducted 6 weeks after first dose, then every 9 weeks until disease progression, up to 16.5 months"
        },
        {
          "measure": "Number of Patients With AEs Receiving Enoblituzumab Plus Retifanlimab",
          "timeFrame": "Throughout the study, up to 16.5 months."
        },
        {
          "measure": "Maximum Drug Concentration or Drug Concentration of Enoblituzumab at the End of Infusion of Enoblituzumab (Cmax)",
          "description": "The highest measured concentration of enoblituzumab in the bloodstream.",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [2 hours]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)"
        },
        {
          "measure": "Maximum Drug Concentration or Drug Concentration of Tebotelimab at the End of Infusion of Tebotelimab (Cmax)",
          "description": "The highest measured concentration of tebotelimab in the bloodstream.",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)"
        },
        {
          "measure": "Maximum Drug Concentration or Drug Concentration of Retifanlimab at the End of Infusion of Enoblituzumab (Cmax)",
          "description": "The highest measured concentration of retifanlimab in the bloodstream.",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)"
        },
        {
          "measure": "Trough Concentration of Enoblituzumab (Ctrough or Cmin)",
          "description": "The amount of enoblituzumab left in the bloodstream before the next dose is given.",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [2 hours]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days"
        },
        {
          "measure": "Trough Concentration of Tebotelimab (Ctrough or Cmin)",
          "description": "The amount of tebotelimab left in the bloodstream before the next dose is given.",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)"
        },
        {
          "measure": "Trough Concentration of Retifanlimab (Ctrough or Cmin)",
          "description": "The amount of retifanlimab left in the bloodstream before the next dose is given.",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)"
        },
        {
          "measure": "Number of Patients Who Develop Antidrug Antibodies (ADA) to Enoblituzumab.",
          "timeFrame": "Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months"
        },
        {
          "measure": "Number of Patients Who Develop ADA to Tebotelimab",
          "timeFrame": "Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months"
        },
        {
          "measure": "Number of Patients Who ADA to Retifanlimab",
          "timeFrame": "Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) not curable by local therapy\n* No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed \\> 6 months prior if given as part of multimodal treatment for locally advanced disease)\n* Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Patients may not have a primary tumor site of upper esophagus, salivary gland, or nasopharynx (any histology)\n* Availability of formalin-fixed, paraffin embedded tumor specimen or contemporary biopsy for immunohistochemical evaluation of pharmacodynamic markers of interest\n* Willing to consent for baseline and on-treatment biopsy.\n* Performance status 0 or 1\n* Life expectancy of 6 months or more\n* Adequate end organ function\n* At least one radiographically measurable lesion\n* PD-L1 expression level that is either\n\n  1. Positive (combined positive score \\[CPS\\] ≥ 1) for the retifanlimab cohort, or\n  2. Negative (CPS \\< 1) for the tebotelimab cohort\n* Results available from human papilloma virus p16 status for oropharyngeal cancer\n* Acceptable laboratory results\n\nExclusion Criteria:\n\n* Disease suitable for local therapy administered with curative intent\n* Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN\n* Radiation or other non-systemic therapy within 2 weeks prior to the first dose of study drug\n* Prior therapy with an anti-B7-H3, anti-PD-1, anti-PD-L1, or anti-LAG-3 agent",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ashley L. Ward, MD",
          "affiliation": "MacroGenics",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "University of Maryland, Greenebaum Comprehensive Cancer Center",
          "city": "Baltimore",
          "state": "Maryland",
          "zip": "21201",
          "country": "United States",
          "geoPoint": {
            "lat": 39.29038,
            "lon": -76.61219
          }
        },
        {
          "facility": "University of Michigan",
          "city": "Ann Arbor",
          "state": "Michigan",
          "zip": "48109",
          "country": "United States",
          "geoPoint": {
            "lat": 42.27756,
            "lon": -83.74088
          }
        },
        {
          "facility": "Comprehensive Cancer Centers of Nevada",
          "city": "Las Vegas",
          "state": "Nevada",
          "zip": "89169",
          "country": "United States",
          "geoPoint": {
            "lat": 36.17497,
            "lon": -115.13722
          }
        },
        {
          "facility": "University of North Carolina - Lineberger Cancer Center",
          "city": "Chapel Hill",
          "state": "North Carolina",
          "zip": "27514",
          "country": "United States",
          "geoPoint": {
            "lat": 35.9132,
            "lon": -79.05584
          }
        },
        {
          "facility": "University of Pennsylvania - Abramson Cancer Center",
          "city": "Philadelphia",
          "state": "Pennsylvania",
          "zip": "19104",
          "country": "United States",
          "geoPoint": {
            "lat": 39.95238,
            "lon": -75.16362
          }
        },
        {
          "facility": "University of Pittsburgh Medical Center- Hillman Cancer Center",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15232",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "Liverpool Hospital",
          "city": "Liverpool",
          "state": "New South Wales",
          "zip": "2170",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.91938,
            "lon": 150.92588
          }
        },
        {
          "facility": "Monash Health, Medical Oncology Department",
          "city": "Ruse",
          "state": "New South Wales",
          "zip": "3168",
          "country": "Australia",
          "geoPoint": {
            "lat": -34.06976,
            "lon": 150.84168
          }
        },
        {
          "facility": "Royal North Shore Hospital",
          "city": "Sydney",
          "state": "New South Wales",
          "zip": "2065",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.86785,
            "lon": 151.20732
          }
        },
        {
          "facility": "Calvary Mater Newcastle",
          "city": "Waratah",
          "state": "New South Wales",
          "zip": "2298",
          "country": "Australia",
          "geoPoint": {
            "lat": -32.90667,
            "lon": 151.72647
          }
        },
        {
          "facility": "Icon Cancer Centre Southport",
          "city": "Southport",
          "state": "Queensland",
          "zip": "4215",
          "country": "Australia",
          "geoPoint": {
            "lat": -27.96724,
            "lon": 153.39796
          }
        },
        {
          "facility": "Andrew Love Cancer Centre, Barwon Health",
          "city": "Geelong",
          "state": "Victoria",
          "zip": "3220",
          "country": "Australia",
          "geoPoint": {
            "lat": -38.14711,
            "lon": 144.36069
          }
        },
        {
          "facility": "Fiona Stanley Hospital",
          "city": "Murdoch",
          "state": "Western Australia",
          "zip": "6150",
          "country": "Australia",
          "geoPoint": {
            "lat": -32.06987,
            "lon": 115.83757
          }
        },
        {
          "facility": "Complex Oncology Center Ruse Ltd.",
          "city": "Dobrich",
          "zip": "7002",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 43.56491,
            "lon": 27.83138
          }
        },
        {
          "facility": "MHAT Serdica",
          "city": "Panagyurishte",
          "zip": "1632",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 42.49518,
            "lon": 24.19021
          }
        },
        {
          "facility": "MBAL Uni Hospital",
          "city": "Pleven",
          "zip": "4500",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 43.41791,
            "lon": 24.61666
          }
        },
        {
          "facility": "MHAT Nadezhda, Medical Oncology",
          "city": "Sofia",
          "zip": "1373",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 42.69751,
            "lon": 23.32415
          }
        },
        {
          "facility": "UMHAT Tsarisa Yoanna - ISUL",
          "city": "Sofia",
          "zip": "1527",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 42.69751,
            "lon": 23.32415
          }
        },
        {
          "facility": "UMHAT Georgi Stranski Medical Oncology Department",
          "city": "Sofia",
          "zip": "5800",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 42.69751,
            "lon": 23.32415
          }
        },
        {
          "facility": "COC Dobrich",
          "city": "Sofia",
          "zip": "9300",
          "country": "Bulgaria",
          "geoPoint": {
            "lat": 42.69751,
            "lon": 23.32415
          }
        },
        {
          "facility": "Bajcsy-Zsilinszky Korhaz",
          "city": "Budapest",
          "zip": "01106",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.49835,
            "lon": 19.04045
          }
        },
        {
          "facility": "Uzsoki Street Hospital",
          "city": "Budapest",
          "zip": "1145",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.49835,
            "lon": 19.04045
          }
        },
        {
          "facility": "Dept of Oncology, University of Debrecen",
          "city": "Debrecen",
          "zip": "04032",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.53167,
            "lon": 21.62444
          }
        },
        {
          "facility": "Dept of Oncology, Bekec County Hosp",
          "city": "Gyula",
          "zip": "5700",
          "country": "Hungary",
          "geoPoint": {
            "lat": 46.65,
            "lon": 21.28333
          }
        },
        {
          "facility": "Dept of Oncology, Tolna County Hospital",
          "city": "Szekszárd",
          "zip": "7100",
          "country": "Hungary",
          "geoPoint": {
            "lat": 46.34723,
            "lon": 18.71189
          }
        },
        {
          "facility": "The Ewa Pilecka Department of Clinical Oncology",
          "city": "Bialystok",
          "zip": "15027",
          "country": "Poland",
          "geoPoint": {
            "lat": 53.13333,
            "lon": 23.16433
          }
        },
        {
          "facility": "Uniwersyteckie Centrum Kliniczne",
          "city": "Gdansk",
          "zip": "80-214",
          "country": "Poland",
          "geoPoint": {
            "lat": 54.35227,
            "lon": 18.64912
          }
        },
        {
          "facility": "I Clinics of Radiotherapy and Chemiotherapy; The Maria Sklodowska-Curie National Research Institute of Oncology",
          "city": "Gliwice",
          "zip": "44-102",
          "country": "Poland",
          "geoPoint": {
            "lat": 50.29761,
            "lon": 18.67658
          }
        },
        {
          "facility": "Biokinetica",
          "city": "Józefów",
          "zip": "05-410",
          "country": "Poland",
          "geoPoint": {
            "lat": 52.13707,
            "lon": 21.23589
          }
        },
        {
          "facility": "Clinics of Head and Neck Cancer, The Maria Sklodowska-Curie National Research Institute of Oncology",
          "city": "Warsaw",
          "country": "Poland",
          "geoPoint": {
            "lat": 52.22977,
            "lon": 21.01178
          }
        },
        {
          "facility": "Complejo Hospitalario Universitario de Badajoz",
          "city": "Badajoz",
          "zip": "06080",
          "country": "Spain",
          "geoPoint": {
            "lat": 38.87789,
            "lon": -6.97061
          }
        },
        {
          "facility": "Hospital Universitario Vall D'Hebrón",
          "city": "Barcelona",
          "zip": "08035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital Clínic de Barcelona",
          "city": "Barcelona",
          "zip": "08036",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital Clínico San Carlos",
          "city": "Madrid",
          "zip": "28040",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Clinica Universidad de Navarra",
          "city": "Pamplona",
          "zip": "31008",
          "country": "Spain",
          "geoPoint": {
            "lat": 42.81687,
            "lon": -1.64323
          }
        },
        {
          "facility": "Hospital Universitario Virgen de la Macarena",
          "city": "Seville",
          "zip": "41009",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.38283,
            "lon": -5.97317
          }
        },
        {
          "facility": "Communal Non-profit Enterprise \"City Clinical Hospital#4\" of Dnipro City",
          "city": "Dnipro",
          "zip": "49102",
          "country": "Ukraine",
          "geoPoint": {
            "lat": 48.46664,
            "lon": 35.04066
          }
        },
        {
          "facility": "Communal Non-Profit Enterprise \"Regional Center of Oncology\", Oncosurgical Department of Head and Neck",
          "city": "Kharkiv",
          "zip": "61070",
          "country": "Ukraine",
          "geoPoint": {
            "lat": 49.98177,
            "lon": 36.25475
          }
        },
        {
          "facility": "Communal Non-profit Enterprise \"Regional Clinical Oncology Center of Kirovohrad Regional Council\",",
          "city": "Kropyvnytskyi",
          "zip": "25000",
          "country": "Ukraine",
          "geoPoint": {
            "lat": 48.50834,
            "lon": 32.26618
          }
        },
        {
          "facility": "Kyiv City Clinical Oncological Centre",
          "city": "Kyiv",
          "zip": "03115",
          "country": "Ukraine",
          "geoPoint": {
            "lat": 50.45466,
            "lon": 30.5238
          }
        },
        {
          "facility": "Municipal Non-Profit Enterprise of Sumy Regional Council \"Sumy Regional Clinical Oncology Dispensary\"",
          "city": "Sumy",
          "zip": "40022",
          "country": "Ukraine",
          "geoPoint": {
            "lat": 50.91741,
            "lon": 34.79906
          }
        },
        {
          "facility": "Communal Nonprofit Enterprise Podilsky Regional Center of Oncology",
          "city": "Vinnytsia",
          "zip": "21029",
          "country": "Ukraine",
          "geoPoint": {
            "lat": 49.2322,
            "lon": 28.46871
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Retifanlimab Cohort",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles"
        },
        {
          "id": "FG001",
          "title": "Tebotelimab Cohort",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "48"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "14"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "48"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "14"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Death",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "10"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                }
              ]
            },
            {
              "type": "Lost to Follow-up",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Study terminated by sponsor",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "35"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "11"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Retifanlimab Cohort",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
        },
        {
          "id": "BG001",
          "title": "Tebotelimab Cohort",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "48"
            },
            {
              "groupId": "BG001",
              "value": "14"
            },
            {
              "groupId": "BG002",
              "value": "62"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "61.2",
                      "spread": "11.31"
                    },
                    {
                      "groupId": "BG001",
                      "value": "65.1",
                      "spread": "6.80"
                    },
                    {
                      "groupId": "BG002",
                      "value": "62.0",
                      "spread": "10.54"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "13"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "38"
                    },
                    {
                      "groupId": "BG001",
                      "value": "11"
                    },
                    {
                      "groupId": "BG002",
                      "value": "49"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "47"
                    },
                    {
                      "groupId": "BG001",
                      "value": "12"
                    },
                    {
                      "groupId": "BG002",
                      "value": "59"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "42"
                    },
                    {
                      "groupId": "BG001",
                      "value": "14"
                    },
                    {
                      "groupId": "BG002",
                      "value": "56"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "Hungary",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "4"
                    }
                  ]
                }
              ]
            },
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "12"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "13"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ukraine",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "12"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "14"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Poland",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "6"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "7"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Bulgaria",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Australia",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "6"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "7"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Spain",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "9"
                    },
                    {
                      "groupId": "BG001",
                      "value": "6"
                    },
                    {
                      "groupId": "BG002",
                      "value": "15"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Overall Response Rate (ORR) of Enoblituzumab Plus Retifanlimab",
          "description": "Investigator-assessed ORR. defined as the percentage of patients in the response evaluable population who achieve the best overall response of complete response (CR) or partial response (PR),per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria..\n\nCR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Number of Patients With Adverse Events (AEs) Receiving Enoblituzumab Plus Tebotelimab",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Throughout the study, up to 16.5 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "12"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "ORR of Enoblituzumab Plus Tebotelimab",
          "description": "Investigator-assessed ORR. ORR, defined as the percentage of patients in the response evaluable population who achieve the a best overall response of complete response (CR) or partial response (PR), per RECIST, version 1.1 criteria.\n\nCR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Progression-free Survival (PFS)",
          "description": "Time from the first dose date to the date of first documented progression or death from any cause, whichever occurs first, evaluated by cohort",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            },
            {
              "id": "OG001",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                },
                {
                  "groupId": "OG001",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "There was an insufficient number of events to calculate PFS."
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "There was an insufficient number of events to calculate PFS."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Disease-control Rate (DCR)",
          "description": "Percentage of response-evaluable patients with CR, PR, or stable disease (SD) for at least 3 months, evaluated by cohort",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            },
            {
              "id": "OG001",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                },
                {
                  "groupId": "OG001",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "19"
                    },
                    {
                      "groupId": "OG001",
                      "value": "5"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Duration of Response",
          "description": "Time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first, evaluated by cohort",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "months",
          "timeFrame": "Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            },
            {
              "id": "OG001",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                },
                {
                  "groupId": "OG001",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "spread": "NA",
                      "comment": "There were an insufficient number of progression events in the analysis population to calculate duration of response."
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "spread": "NA",
                      "comment": "There were an insufficient number of progression events in the analysis population to calculate duration of response."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Overall Survival",
          "description": "Time from the first dose date to the date of death from any cause, evaluated by cohort",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            },
            {
              "id": "OG001",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                },
                {
                  "groupId": "OG001",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "There were an insufficient number of death events in the analysis population to calculate overall survival."
                    },
                    {
                      "groupId": "OG001",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "There were an insufficient number of death events in the analysis population to calculate overall survival."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Best Overall Response (BOR)",
          "description": "The participants best response to treatment during their study participation. Responses are categorized as CR, PR, stable disease (SD), progressive disease (PD), or not evaluated (NE), per RECIST 1.1 criteria CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions, and non-PD in non-target lesions PD is defined as at least a 20% increase from nadir in the sum of diameters of target lesions or unequivocal progression in non-target lesions SD is defined as non-PD in target and non-target lesions",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Tumor assessment is conducted 6 weeks after first dose, then every 9 weeks until disease progression, up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles"
            },
            {
              "id": "OG001",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                },
                {
                  "groupId": "OG001",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "Complete Response",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Partial Response",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Stable Disease",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20"
                    },
                    {
                      "groupId": "OG001",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "Progressive Disease",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    },
                    {
                      "groupId": "OG001",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "Not Evaluable",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "10"
                    },
                    {
                      "groupId": "OG001",
                      "value": "5"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Patients With AEs Receiving Enoblituzumab Plus Retifanlimab",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Throughout the study, up to 16.5 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "40"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Maximum Drug Concentration or Drug Concentration of Enoblituzumab at the End of Infusion of Enoblituzumab (Cmax)",
          "description": "The highest measured concentration of enoblituzumab in the bloodstream.",
          "populationDescription": "Participants who received Enoblituzumab and had at least 1 end of infusion PK sample. As pre-specified in the PK analysis plan, Enoblituzumab PK data from both arms of the study were combined for analysis since Enoblituzumab dose was schedule were consistent across both arms.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [2 hours]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Enoblituzumab",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "62"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "505.3",
                      "spread": "130.5"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Maximum Drug Concentration or Drug Concentration of Tebotelimab at the End of Infusion of Tebotelimab (Cmax)",
          "description": "The highest measured concentration of tebotelimab in the bloodstream.",
          "populationDescription": "Participants who received tebotelimab and had at least 1 End of Infusion PK sample",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "196.5",
                      "spread": "74.8"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Maximum Drug Concentration or Drug Concentration of Retifanlimab at the End of Infusion of Enoblituzumab (Cmax)",
          "description": "The highest measured concentration of retifanlimab in the bloodstream.",
          "populationDescription": "Participants who received retifanlimab and had at least 1 end of infusion PK sample.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "47"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "113.1",
                      "spread": "26.9"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Trough Concentration of Enoblituzumab (Ctrough or Cmin)",
          "description": "The amount of enoblituzumab left in the bloodstream before the next dose is given.",
          "populationDescription": "Participants who received enoblituzumab and had at least 1 pre-infusion PK sample. As pre-specified in the PK analysis plan, enoblituzumab PK data from both arms of the study were combined for analysis since enoblituzumab dose and schedule were consistent across both arms.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [2 hours]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days",
          "groups": [
            {
              "id": "OG000",
              "title": "Enoblituzumab",
              "description": "Enoblituzumab 15 mg/kg"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "62"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "165.7",
                      "spread": "88.8"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Trough Concentration of Tebotelimab (Ctrough or Cmin)",
          "description": "The amount of tebotelimab left in the bloodstream before the next dose is given.",
          "populationDescription": "Participants who received tebotelimab and had at least 1 pre-infusion PK sample.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20.1",
                      "spread": "6.1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Trough Concentration of Retifanlimab (Ctrough or Cmin)",
          "description": "The amount of retifanlimab left in the bloodstream before the next dose is given.",
          "populationDescription": "Participants who received retifanlimab and had at least 1 pre-infusion PK sample.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Cycle 1 Day 1: Pre-infusion, end of infusion (EOI [1 hour]), 4 hours after EOI; Cycle 1 Days 2, 3, 8 and 15 at any time; On Day 1 of Cycles 2, 3, 4, 5 and 6: Pre-infusion and EOI (each cycle is 21 days)",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "33"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "31.2",
                      "spread": "15.5"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Patients Who Develop Antidrug Antibodies (ADA) to Enoblituzumab.",
          "populationDescription": "As pre-specified in the PK analysis plan, enoblituzumab ADA data from both arms of the study were combined for analysis since enoblituzumab dose and schedule were consistent across both arms.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Enoblituzumab",
              "description": "Enoblituzumab 15 mg/kg"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "62"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "Not done at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "Not done at baseline, positive at least once post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, not done post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "37"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, positive at least once post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "positive at baseline, not done post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    }
                  ]
                },
                {
                  "title": "positive at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    }
                  ]
                },
                {
                  "title": "positive at baseline, positive at least once post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Patients Who Develop ADA to Tebotelimab",
          "populationDescription": "Only participants receiving tebotelimab were analyzed for the presence of tebotelimab ADA.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Tebotelimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "14"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "not done at baseline, positive at least once post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, not done post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "7"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, positive at least once post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "positive at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Patients Who ADA to Retifanlimab",
          "populationDescription": "Only participants receiving retifanlimab were analyzed for the presence of retifanlimab ADA.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Prior to treatment (baseline) and at the beginning of every 3-week cycle of treatment (post baseline) up to 16.5 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Retifanlimab Cohort",
              "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "48"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "Not done at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, not done post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "8"
                    }
                  ]
                },
                {
                  "title": "negative at baseline, negative post baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "37"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "Throughout the study, up to 16.5 months",
      "description": "AEs are based on physical exam, participant reports and significant abnormal laboratory values.\n\nAEs were not collected during the survival follow up. Serious AEs (SAEs) were collected in survival follow up, if considered related to study treatment by the investigator..\n\nProgression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Retifanlimab Cohort",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks",
          "deathsNumAffected": 10,
          "deathsNumAtRisk": 48,
          "seriousNumAffected": 14,
          "seriousNumAtRisk": 48,
          "otherNumAffected": 40,
          "otherNumAtRisk": 48
        },
        {
          "id": "EG001",
          "title": "Tebotelimab Cohort",
          "description": "Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks",
          "deathsNumAffected": 3,
          "deathsNumAtRisk": 14,
          "seriousNumAffected": 6,
          "seriousNumAtRisk": 14,
          "otherNumAffected": 12,
          "otherNumAtRisk": 14
        }
      ],
      "seriousEvents": [
        {
          "term": "Blood loss anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Atrial fibrillation",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Cardiotoxicity",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Immune-mediated myocarditis",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Tracheo-oesophageal fistula",
          "organSystem": "Congenital, familial and genetic disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Immune-mediated endocrinopathy",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Dysphagia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Immune-mediated enterocolitis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Upper gastrointestinal haemorrhage",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Cytomegalovirus gastritis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Lower respiratory tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pneumonia aspiration",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Wound infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Tumour haemorrhage",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pulmonary embolism",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pneumonitis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pulmonary haemorrhage",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Respiratory tract haemorrhage",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Fungating wound",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Gastrostomy",
          "organSystem": "Surgical and medical procedures",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Shock haemorrhagic",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Eosinophilia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Lymphopenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Thrombocytopenia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Cardiac failure",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Palpitations",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Sinus bradycardia",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypothyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 6,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hyperthyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Constipation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Dysphagia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Abdominal pain upper",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Mouth haemorrhage",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Oral pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Stomatitis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Abdominal pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Flatulence",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Gastrooesophageal reflux disease",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Odynophagia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Salivary hypersecretion",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Swollen tongue",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 6,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Oedema peripheral",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Asthenia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 2,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Axillary pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Chest discomfort",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Inadequate analgesia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Swelling face",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Cytokine release syndrome",
          "organSystem": "Immune system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "COVID-19",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Oral candidiasis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Breakthrough COVID-19",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Respiratory tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Urinary tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Candida infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Cellulitis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Coronavirus infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Enterococcal infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Escherichia infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Gastroenteritis staphylococcal",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Gingival abscess",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Klebsiella infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pharyngitis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Sepsis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Skin infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Staphylococcal bacteraemia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Tooth infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Tracheostomy infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Upper respiratory tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Wound infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Infusion related reaction",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 5,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 4,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Incision site pain",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Incision site ulcer",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Skin abrasion",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Toxicity to various agents",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Lipase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 5,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Weight decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "White blood cell count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Lymphocyte count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Amylase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Blood creatine phosphokinase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Blood pressure increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "N-terminal prohormone brain natriuretic peptide increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 2,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Neutrophil count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Alanine aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Aspartate aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Blood creatinine increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Blood thyroid stimulating hormone increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Coronavirus test positive",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Electrocardiogram QT prolonged",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Platelet count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "SARS-CoV-2 test positive",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Transaminases increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Troponin increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Decreased appetite",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypercalcaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypoalbuminaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypokalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hyponatraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypouricaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hyperkalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypocalcaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypophosphataemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Iron deficiency",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Malnutrition",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Steroid diabetes",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pain in extremity",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Muscular weakness",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Musculoskeletal chest pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Flank pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Myalgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Neck pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Acrochordon",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Tumour pain",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 2,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Carotid artery stenosis",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Dysarthria",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypoaesthesia",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Seizure",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Syncope",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Anxiety",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Depression",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Dyspnoea exertional",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Oropharyngeal pain",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Sputum discoloured",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Increased bronchial secretion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Rhinitis allergic",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Tracheal pain",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Pruritus",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Intertrigo",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Rash",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Rash pruritic",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Skin ulcer",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypotension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Embolism",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Flushing",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        },
        {
          "term": "Hypertension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 25.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 48
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 14
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "LTE60",
        "restrictiveAgreement": true
      },
      "pointOfContact": {
        "title": "Chief Medical Officer",
        "organization": "MacroGenics, Inc.",
        "email": "info@macrogenics.com",
        "phone": "301-251-5172"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2020-12-16",
          "uploadDate": "2023-05-30T07:36",
          "filename": "Prot_000.pdf",
          "size": 6765410
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2021-01-11",
          "uploadDate": "2023-05-12T15:14",
          "filename": "SAP_001.pdf",
          "size": 4418438
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-11",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2023-06-23",
            "type": "ACTUAL"
          }
        }
      }
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D006258",
          "term": "Head and Neck Neoplasms"
        },
        {
          "id": "D000077195",
          "term": "Squamous Cell Carcinoma of Head and Neck"
        }
      ],
      "ancestors": [
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D002294",
          "term": "Carcinoma, Squamous Cell"
        },
        {
          "id": "D002277",
          "term": "Carcinoma"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        }
      ]
    }
  },
  "hasResults": true
}